Rabeprazole
Active ingredient: Rabeprazole Sodium
In short: Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ra
What is Rabeprazole used for?
Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered.
Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months.
Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks.
Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
Rabeprazole sodium delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with
H. pyloriinfection and duodenal ulcer disease (active or history within the past 5 years) to eradicate
H. pylori. Eradication of
H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility testing should be done. …
Rabeprazole dosage
Table 1 shows the recommended dosage of rabeprazole sodium delayed-release tablets in adults and adolescent patients 12 years of age and older. The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Use another rabeprazole formulation for pediatric patients 1 year to less than 12 years of age.
Table 1: Recommended Dosage and Duration of Rabeprazole sodium delayed-release tablets in Adults and Adolescents 12 Years of Age and Older
Indication | Dosage of Rabeprazole sodium delayed-release tablets | Treatment Duration
Adults
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) | 20 mg once daily | 4 to 8 weeks*
Maintenance of Healing of Erosive or Ulcerative GERD | 20 mg once daily | Controlled studies do not extend beyond 12 months
Symptomatic GERD in Adults | 20 mg once daily | Up to 4 weeks**
Healing of Duodenal Ulcers | 20 mg once daily after the morning meal | Up to 4 weeks***
Helicobacter pyloriEradication to Reduce the Risk of Duodenal Ulcer Recurrence | Rabeprazole Sodium Delayed-Release Tablets
20 mg Amoxicillin 1,000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen
| 7 days
Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome | Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered | As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year
Adolescents 12 Years of Age and Older
Symptomatic GERD | 20 mg once daily | Up to 8 weeks
* For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered.
** If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.
*** Most patients heal within 4 weeks; some patients may require additional therapy to achieve healing.
Administration Instructions
• Swallow rabeprazole sodium delayed-release tablets whole. Do not chew, crush, or split tablets.
• For the treatment of duodenal ulcers take rabeprazole sodium delayed-release tablets after a meal.
• For
Helicobacter pylorieradication take rabeprazole sodium delayed-release tablets with food.
• For all other indications rabeprazole sodium delayed-release tablets can be taken with or without food.
Take a missed dose as soon as possible. …
How to take Rabeprazole — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Acute Tubulointerstitial NephritisAdvise the patient or caregiver to call the patient’s healthcare provider immediately if they experience signs and/or symptoms associated with -acute tubulointerstitial nephritis
.
Clostridium difficile
-Associated DiarrheaAdvise the patient or caregiver to immediately call the patient’s healthcare provider if they experience diarrhea that does not improve
.
Bone FractureAdvise the patient or caregiver to report any fractures, especially of the hip, wrist or spine, to the patient’s healthcare provider
.
Severe Cutaneous Adverse Reactions
Advise the patient or caregiver to discontinue rabeprazole sodium delayed-release tablets and report any signs and symptoms of a severe cutaneous adverse reaction or other sign of hypersensitivity to the healthcare provider
.
Cutaneous and Systemic Lupus Erythematosus Advise the patient or caregiver to immediately call the patient’s healthcare provider for any new or worsening of symptoms associated with cutaneous or systemic lupus erythematosus
. …
Warnings & precautions
Do not take this medicine if: Rabeprazole is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria .
PPIs, including rabeprazole, are contraindicated with rilpivirine-containing products .
For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with rabeprazole sodium delayed-release tablets, refer to the
Contraindicationssection of their package inserts.
In adults, symptomatic response to therapy with rabeprazole sodium delayed-release tablets does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI.
Steady state interactions of rabeprazole and warfarin have not been adequately evaluated in patients. There have been reports of increased INR and prothrombin time in patients receiving a proton pump inhibitor and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with rabeprazole sodium delayed-release tablets and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time
.
Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions, to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia). …
Rabeprazole side effects
The following serious adverse reactions are described below and elsewhere in labeling:
Acute Tubulointerstitial Nephritis
Clostridium difficile-Associated Diarrhea
Bone Fracture
Cutaneous and Systemic Lupus Erythematosus
Cyanocobalamin (Vitamin B-12) Deficiency
Hypomagnesemia and Mineral Metabolism
Fundic Gland Polyps
Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The data described below reflect exposure to rabeprazole sodium delayed-release tablets in 1,064 adult patients exposed for up to 8 weeks. The studies were primarily placebo-and active-controlled trials in adult patients with Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers and Gastric Ulcers. The population had a mean age of 53 years (range 18 to 89 years) and had a ratio of approximately 60% male: 40% female. The racial distribution was 86% Caucasian, 8% African American, 2% Asian, and 5% other. Most patients received either 10 mg, 20 mg or 40 mg per day of rabeprazole sodium delayed-release tablets. …
Drug interactions
Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them.
Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole sodium delayed-release tablets and Interactions with Diagnostics
Antiretrovirals
Clinical Impact: | The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance.
• Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with rabeprazole may increase toxicity
.
• There are other antiretroviral drugs which do not result in clinically relevant interactions with rabeprazole.
Intervention: | Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated
. …
About this medicine
The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium, which is a proton pump inhibitor. It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1
H–benzimidazole sodium salt. It has an empirical formula of C
18H
20N
3NaO
3S and a molecular weight of 381.42. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform, and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is:
Rabeprazole sodium delayed-release tablets is available for oral administration as Delayed-Release, enteric-coated tablets containing 20 mg of rabeprazole sodium. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 63e0b7ca-6b2d-42a9-b9d4-4523b8a20425. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate